Russell Investments Group Ltd. Has $1.85 Million Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Russell Investments Group Ltd. trimmed its holdings in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 38.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 140,965 shares of the company’s stock after selling 86,633 shares during the quarter. Russell Investments Group Ltd. owned about 0.11% of Centessa Pharmaceuticals worth $1,852,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in CNTA. American Century Companies Inc. increased its holdings in Centessa Pharmaceuticals by 3.5% in the second quarter. American Century Companies Inc. now owns 1,130,708 shares of the company’s stock worth $14,858,000 after purchasing an additional 37,954 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Centessa Pharmaceuticals by 29.2% in the 2nd quarter. Legal & General Group Plc now owns 98,256 shares of the company’s stock valued at $1,291,000 after acquiring an additional 22,205 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Centessa Pharmaceuticals by 155.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 428,434 shares of the company’s stock valued at $5,630,000 after acquiring an additional 260,702 shares during the period. Ensign Peak Advisors Inc boosted its stake in Centessa Pharmaceuticals by 27.8% during the second quarter. Ensign Peak Advisors Inc now owns 559,744 shares of the company’s stock worth $7,355,000 after acquiring an additional 121,611 shares in the last quarter. Finally, Candriam S.C.A. acquired a new stake in Centessa Pharmaceuticals in the second quarter worth $4,568,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $22.41, for a total transaction of $134,460.00. Following the transaction, the general counsel directly owned 105,386 shares of the company’s stock, valued at $2,361,700.26. This trade represents a 5.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Mario Alberto Accardi sold 10,000 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the transaction, the insider owned 178,801 shares in the company, valued at approximately $5,364,030. This trade represents a 5.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 113,172 shares of company stock worth $2,820,441. Corporate insiders own 7.09% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA opened at $29.57 on Thursday. The firm has a market capitalization of $3.97 billion, a P/E ratio of -16.16 and a beta of 1.55. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $9.60 and a 52 week high of $30.58. The stock has a 50 day moving average price of $25.42 and a two-hundred day moving average price of $19.54. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). Equities analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

CNTA has been the topic of several research reports. Stephens assumed coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, October 28th. They set an “overweight” rating and a $35.00 price objective on the stock. Wall Street Zen raised Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 27th. B. Riley increased their price target on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, December 1st. Truist Financial set a $30.00 price objective on Centessa Pharmaceuticals in a report on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $37.70.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.